Zhejiang Ausun Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.14

Zhejiang Ausun Pharmaceutical Co., Ltd. Debt to Equity Ratio is 0.14 for the year ending December 31, 2023, a -14.78% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Zhejiang Ausun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.17, a 89.07% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.09, a 140.54% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.04, a -47.73% change year over year.
Zhejiang Ausun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.07, a -42.16% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shanghai Stock Exchange: 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd.

CEO	Mr. Zhiguo Zheng
IPO Date	May 9, 2017
Location	China
Headquarters	No. 5 Donghai Fourth Lane
Employees	1,174
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials

Description

Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it is involved in the processing, and research and development business. The company was founded in 2010 is based in Linhai, China.

Key trends

Past 5 years